Dual-payload antibody-drug conjugates and use thereof
A dual-load bifunctional CDN conjugate addresses the limitations of CDN-type STING agonists and ADCs by combining immune-activating and cytotoxic molecules, achieving effective and safe tumor suppression through diverse administration routes.
Patent Information
- Application Number
- TW114133944
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-29
- Filing Date
- 2025-09-04
- Publication Date
- 2026-07-01
AI Technical Summary
Current CDN-type STING agonists face challenges such as easy degradation by enzymes, short half-life, limited bioavailability, and reliance on intratumoral administration, which restricts their use as systemic immunotherapy, and ADCs face issues like uncontrolled payload release, off-target toxicity, and complex pharmacokinetics.
Development of a dual-load bifunctional cyclic dinucleotide conjugate drug that combines a CDN STING agonist with a second payload, targeted by specific guide molecules through linker units, forming a single ADC molecule that can be administered via intravenous, subcutaneous, or topical routes.
The dual-load conjugate achieves synergistic tumor suppression, improved efficacy, and safety, with enhanced tumor cell endocytosis, and provides immune-activating and cytotoxic mechanisms, expanding administration methods and beneficiary populations.